Amylin Pharmaceuticals Inc. (AMLN) (AMLN), the diabetes drugmaker that’s up for sale, has received first-round bids from Sanofi (SAN) and Merck & Co. said three people familiar with the process. The companies made offers of at least $25 a share, said the people, who declined to be identified as the deliberations are private.
duh huh! OF at least $25 and at least 2 not bid yet (likely even higher) and remember this is just the first round, so you have to figure the winning bid if closed this week would have to be at least $28 - final winning bid in the least $33....imo.
This guy is a short and doesn't know how to read !!!Where does the article say "only 2" and where does it say AT $25/shr ?Learn to read before posting...
Don't tellme you're short this one too, Lyongy. Don't you ever learn?